Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07242118 · ClinicalTrials.gov registry record · NA

Conformal Ablative Radiotherapy in Older Women (CARMEN) With Breast Cancer Undergoing Non-Operative Management

A NA study of Breast Cancer Female, sponsored by University of Kansas Medical Center.

Recruiting
Registry status
NA
Development phase
18
Enrollment target
2
Study locations

NCT07242118 is a NA study of Breast Cancer Female that is actively recruiting participants, run by University of Kansas Medical Center. The registered enrollment target is 18 participants, below the 692-participant average among 46 other Breast Cancer Female trials with a reported enrollment target (97% lower). The trial reports 2 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07242118, a NA study of Breast Cancer Female, is actively recruiting participants, sponsored by University of Kansas Medical Center.

RECRUITING
Registry status
NA
Development phase
18 participants
Enrollment target
2
Study locations

Study Summary

This phase II study evaluates SABR as non-operative treatment for women aged 65+ with ER-positive, HER2-negative breast cancer ≤5 cm and no lymph node involvement. Eligible patients, including those previously on endocrine therapy, receive 5 SABR treatments, followed by monitoring of quality of life and assessment of treatment-related toxicity.

Conditions Studied

Interventions

  • RADIATION SABR

Study Locations (2)

Kansas

  • University of Kansas Medical Center - Kansas City
  • University of Kansas Medical Center - Kansas City

Trial Details

FieldValue
Enrollment Target 18 participants
Start Date 2025-11-04
Est. Completion 2027-10
Phase NA

Sponsor

University of Kansas Medical Center

408 total trials

What the Registry Record Tells You About NCT07242118

The ClinicalTrials.gov registry entry for NCT07242118 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 692-participant average among 46 other Breast Cancer Female trials with a reported enrollment target (97% lower). The listed sponsor is University of Kansas Medical Center, which has 408 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Breast Cancer Female appearing as the primary indexed condition, and to 1 intervention - of which SABR is the first listed.

NCT07242118 reports 2 study locations spanning 1 distinct geographic area - top geographies include Kansas.

Frequently Asked Questions

What is clinical trial NCT07242118 about?

NCT07242118 is a clinical study titled "Conformal Ablative Radiotherapy in Older Women (CARMEN) With Breast Cancer Undergoing Non-Operative Management". This phase II study evaluates SABR as non-operative treatment for women aged 65+ with ER-positive, HER2-negative breast cancer ≤5 cm and no lymph node involvement. Eligible patients, including those previously on endocrine therapy, receive 5 SABR treatments, followed by monitoring of quality of life...

What is the current status of trial NCT07242118?

This trial is currently recruiting. It is a NA study. The enrollment target is 18 participants. The study started on 2025-11-04. Estimated completion is 2027-10.

What conditions does trial NCT07242118 study?

This clinical trial studies the following conditions: Breast Cancer Female.

What interventions are being tested in trial NCT07242118?

The interventions under investigation include: SABR (RADIATION).

Who is sponsoring clinical trial NCT07242118?

This trial is sponsored by University of Kansas Medical Center, which has 408 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07242118 being conducted?

This trial has 2 study locations across Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Breast Cancer Female

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.